文献速递临床免疫分子诊断

COVID19SEROSpeed IgM/IgG快速检测对SARS-CoV-2感染的诊断性能:欧洲多中心研究

Performance of the COVID19SEROSpeed IgM/IgG Rapid Test, an Immunochromatographic Assay for the Diagnosis of SARS-CoV-2 Infection: a Multicenter European Study.
PubMed 文献 · J Clin Microbiol · 2021-01-21

该研究评估COVID19SEROSpeed IgM/IgG快速检测(BioSpeedia)与其他商业抗体检测相比的诊断性能。在215份大流行前血清中临床特异性为98.1%(95%CI 96.2%–99.4%),在710份qRT-PCR确诊血清中总体临床敏感性为86.0%(95%CI 0.83–0.89),与Euroimmun检测一致性良好。

要点

  • BioS快速检测在215份大流行前血清中特异性达98.1%。
  • 在710份确诊血清中总体敏感性86.0%,与Euroimmun一致性0.91。
  • 症状出现≥11天时BioS阳性符合率最高,早于11天有78.2%检出抗体。

核心结论

  • BioS IgM/IgG快速检测特异性高,阳性符合率高于本研究中所有ELISA/CLIA商业检测。
  • 该检测可在症状出现后11天前检出抗体,提高早期诊断效率。

研究设计与样本

  • 多中心欧洲研究,临床特异性评估215份大流行前血清(含病毒感染或自身免疫病患者)。
  • 临床敏感性评估710份来自564例qRT-PCR确诊患者的血清,并与五种商业检测比较。
  • 另分析7例有症状患者的抗体应答动力学。

主要发现

  • 大流行前标本特异性98.1%(95%CI 96.2%–99.4%)。
  • 710份大流行标本总体临床敏感性86.0%(95%CI 0.83–0.89)。
  • 与Euroimmun检测总体一致性0.91,Cohen's kappa系数0.62。
  • 症状出现≥11天时BioS阳性符合率最高。
  • 78.2%的患者在症状出现11天前可检出抗体。

关键数值与推荐

  • 特异性98.1%(95%CI 96.2%–99.4%,n=215份大流行前血清)。
  • 总体临床敏感性86.0%(95%CI 0.83–0.89,n=710份标本)。
  • 与Euroimmun总体一致性0.91,Cohen's kappa系数0.62。

临床怎么用

  • 可用于SARS-CoV-2抗体检测,尤其在高特异性需求场景。
  • 对症状出现后早期(<11天)患者具有较好抗体检出能力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This study assessed the diagnostic performance of the new COVID19SEROSpeed IgM/IgG rapid test (BioSpeedia, a spinoff of the Pasteur Institute of Paris) for the detection of antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in comparison to other commercial antibody assays through a large cross-European investigation. The clinical specificity was assessed on 215 prepandemic sera (including some from patients with viral infections or autoimmune disorders). The clinical sensitivity was evaluated on 710 sera from 564 patients whose SARS-CoV-2 infection was confirmed by quantitative reverse transcription-PCR (qRT-PCR) and whose antibody response was compared to that measured by five other commercial tests. The kinetics of the antibody response were also analyzed in seven symptomatic patients. The specificity of the test (BioS) on prepandemic specimens was 98.1% (95% confidence interval [CI], 96.2% to 99.4%). When tested on the 710 pandemic specimens, BioS showed an overall clinical sensitivity of 86.0% (95% CI, 0.83 to 0.89), with good concordance with the Euroimmun assay (overall concordance of 0.91; Cohen's kappa coefficient of 0.62). Due in part to simultaneous detection of IgM and IgG for both S1 and N proteins, BioS exhibited the highest positive percent agreement at ≥11 days post-symptom onset (PSO). In conclusion, the BioS IgM/IgG rapid test was highly specific and demonstrated a higher positive percentage of agreement than all the enzyme-linked immunosorbent assay/chemiluminescence immunoassay (ELISA/CLIA) commercial tests considered in this study. Moreover, by detecting the presence of antibodies prior to 11 days PSO in 78.2% of the patients, the BioS test increased the efficiency of the diagnosis of SARS-CoV-2 infection in the early stages of the disease.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Plebani M, Parčina M, Bechri I, et al. Performance of the COVID19SEROSpeed IgM/IgG Rapid Test, an Immunochromatographic Assay for the Diagnosis of SARS-CoV-2 Infection: a Multicenter European Study. J Clin Microbiol. 2021. PMID: 33218990. doi:10.1128/JCM.02240-20

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。